Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Clinical trial NCT05378464 · SUSPENDED

Trial details

NCT number: NCT05378464
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2022-05-31
Primary completion: 2026-08-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.